|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K2317/56 | (2013.01) |
| C07K 16/28 | (2006.01) | ||
| A61K 35/17 | (2025.01) | ||
| C07K2319/33 | (2013.01) | ||
| C07K 19/00 | (2006.01) | ||
| A61K 38/00 | (2013.01) | ||
| A61K 39/395 | (2006.01) | ||
| C07K 16/2878 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 14/7051 | (2013.01) | ||
| C07K 14/70517 | (2013.01) | ||
| C07K 14/70578 | (2013.01) | ||
| A61K 31/7076 | (2013.01) | ||
| C07K2319/02 | (2013.01) | ||
| C07K2319/03 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K2317/73 | (2013.01) | ||
| C07K2317/92 | (2013.01) | ||
| C07K2317/622 | (2013.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 37/04 | (2018.01) | ||
| C12N 5/0646 | (2013.01) | ||
| A61K2239/48 | (2023.05) | ||
| C12N 5/0636 | (2013.01) | ||
| A61K2239/38 | (2023.05) | ||
| A61K 40/11 | (2025.01) | ||
| A61K 40/31 | (2025.01) | ||
| A61K 40/4215 | (2025.01) |
| (11) | Patento numeris | 3757128 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 20172811.0 |
| Europos patento paraiškos padavimo data | 2016-03-30 | |
| (97) | Europos patento paraiškos paskelbimo data | 2020-12-30 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2025-06-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201562146825 P | 2015-04-13 | US | |
| 201662286473 P | 2016-01-25 | US | |
| 201662301177 P | 2016-02-29 | US |
| (72) |
KUO, Tracy Chia-Chien , US
CHAPARRO RIGGERS, Javier Fernando , US
SASU, Barbra Johnson , US
GALETTO, Roman , FR
BOLDAJIPOUR, Bijan Andre , US
SOMMER, Cesar Adolfo , US
VAN BLARCOM, Thomas John , US
PERTEL, Thomas Charles , US
RAJPAL, Arvind , US
DUCHATEAU, Philippe , FR
JUILLERAT, Alexandre , US
VALTON, Julien , FR
|
| (73) |
Pfizer Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN |